Group A (n=33) |
Group B (n=25) |
Group C (n=42) | |
Mean age at time of referral (years) | 51 | 54 | 55 |
Sex (male/female) | 3/30 | 4/21 | 2/40 |
Xerogenic medication | 10 (30%) | 15 (60%) | 23 (55%) |
Chronic fatigue | 21 (63%) | 19 (76%) | 29 (69%) |
Salivary gland swelling1-150 | 17 (51%) | 7 (28%) | 8 (19%) |
Connective tissue disease | 0 (0%) | RA: 14 (56%) | RA: 7 (17%) |
SLE: 4 (16%) | SLE: 2 (5%) | ||
Scleroderma: 1 (4%) | Scleroderma: 1 (2%) | ||
CREST: 1 (4%) | |||
Vasculitis: 1 (4%) | |||
PBC: 1 (4%) | |||
Polymyositis: 1 (4%) | |||
Overlap syndrome: 2 (8%) | |||
Positive salivary gland biopsy | 32 (97%) | 24 (96%) | 0 (0%) |
Positive serology | |||
SSA | 28 (85%) | 13 (52%) | 3 (7%) |
SSB | 15 (45%) | 8 (32%) | 1 (2%) |
Positive eye test1-151 | 25 (76%) | 17 (68%) | 18 (43%) |
Parotid sialography1-152 | |||
Sialectasia (positive for SS) | 28 (100%) | 16 (76%) | 3 (8%) |
Subjective complaints1-153 | |||
Dry eyes | 24 (73%) | 20 (80%) | 28 (67%) |
Dry mouth | 32 (96%) | 23 (92%) | 31 (74%) |
Group A, patients with primary SS; group B, patients with secondary SS; group C, patients who tested negative for SS.
↵1-150 Present at first visit.
↵1-151 According to European criteria (at least one positive eye test).6
↵1-152 According to Blatt,50 percentages based on the number of patients with available information.
↵1-153 According to definition by European classification criteria.6
RA, Rheumatoid arthritis; SLE, systemic lupus erythematosus; CREST, calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, telangiectasis; PBC, primary biliary cirrhosis.